Karyopharm Therapeutics (KPTI) - News Mentions

Sign up to add (KPTI) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 2 0%
Gilead Sciences
Gilead Sciences
GILD		 1 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.com
November 22
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
November 20
Karyopharm Therapeutics : MPN 2024 SENTRY Ph 1 presentation
November 14
What is HC Wainwright’s Estimate for KPTI FY2024 Earnings?
November 9
Karyopharm Therapeutics Reports Q3 2024 Financial Results and Corporate Progress
November 8
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
November 7
Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations
November 5
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
November 5
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
November 5
Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript
November 5
Karyopharm Therapeutics: Q3 Earnings Snapshot
November 5
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
November 4
Karyopharm Therapeutics Inc. 2024 Q3 - Results - Earnings Call Presentation
November 4
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
November 3
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 1
Karyopharm Therapeutics Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
October 31

Month over Month

Est. daily news mentions.

Oct 2024 0
Sep 2024 0
Aug 2024 0
Jul 2024 0
Jun 2024 1

How often is Karyopharm Therapeutics mentioned in the news?

Karyopharm Therapeutics was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Karyopharm Therapeutics performing compared to its industry peers?

Karyopharm Therapeutics underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Karyopharm Therapeutics in the last month?

There has been no significant change in the number of news mentions for Karyopharm Therapeutics' compared to the last month.

Why is it important to track news mentions for Karyopharm Therapeutics?

By monitoring mentions in the news for Karyopharm Therapeutics, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Karyopharm Therapeutics, ultimately improving their investment strategies.

Sign up and get more insights on Karyopharm Therapeutics.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact